Olorofim对足菌肿主要病原体足马杜拉菌具有高敏感性
本研究通过计算机模拟比较靶基因二氢乳清酸脱氢酶(DHODH)及体外药敏试验,评估新型抗真菌药olorofim对足马杜拉菌的活性。结果显示,足马杜拉菌与烟曲霉的DHODH结合残基高度相似,olorofim体外活性优异,MIC范围为0.004–0.125 mg/L,MIC90为0.063 mg/L,且与伊曲康唑联合呈无关作用。结论认为olorofim应进一步在体内评估作为足菌肿治疗选择。
要点
- Olorofim对足马杜拉菌体外活性强,MIC90为0.063 mg/L。
- Olorofim的MIC值多比伊曲康唑低一个稀释度。
- Olorofim与伊曲康唑体外联合呈无关作用。
核心结论
- Olorofim对足马杜拉菌具有强效体外活性,应进一步在体内评估作为足菌肿治疗选择。
研究设计与样本
- 通过计算机模拟比较足马杜拉菌与烟曲霉的DHODH靶基因,并进行体外药敏试验及olorofim与伊曲康唑的体外相互作用研究。
主要发现
- 足马杜拉菌与烟曲霉在DHODH DNA序列的7个预测结合残基中共享6个。
- Olorofim对足马杜拉菌的MIC范围为0.004–0.125 mg/L,MIC90为0.063 mg/L。
- Olorofim的MIC值多比伊曲康唑低一个稀释度。
- Olorofim与伊曲康唑体外联合呈无关作用。
关键数值与推荐
- Olorofim对足马杜拉菌的MIC范围为0.004–0.125 mg/L,MIC90为0.063 mg/L。
- Olorofim的MIC值多比伊曲康唑低一个稀释度。
- Olorofim与伊曲康唑体外联合呈无关作用。
临床怎么用
- Olorofim可作为足菌肿潜在治疗选择,但目前仅限体外证据,需进一步体内评估。
局限性
- 本研究仅为体外及计算机模拟分析,未进行体内疗效评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Eumycetoma is currently treated with a combination of itraconazole therapy and surgery, with limited success. Recently, olorofim, the lead candidate of the orotomides, a novel class of antifungal agents, entered a Phase II trial for the treatment of invasive fungal infections. Here we determined the activity of olorofim against Madurella mycetomatis, the main causative agent of eumycetoma. METHODS: Activity of olorofim against M. mycetomatis was determined by in silico comparison of the target gene, dihydroorotate dehydrogenase (DHODH), and in vitro susceptibility testing. We also investigated the in vitro interaction between olorofim and itraconazole against M. mycetomatis. RESULTS: M. mycetomatis and Aspergillus fumigatus share six out of seven predicted binding residues in their DHODH DNA sequence, predicting susceptibility to olorofim. Olorofim demonstrated excellent potency against M. mycetomatis in vivo with MICs ranging from 0.004 to 0.125 mg/L and an MIC90 of 0.063 mg/L. Olorofim MICs were mostly one dilution step lower than the itraconazole MICs. In vitro interaction studies demonstrated that olorofim and itraconazole work indifferently when combined. CONCLUSIONS: We demonstrated olorofim has potent in vitro activity against M. mycetomatis and should be further evaluated in vivo as a treatment option for this disease.
引用
- Lim W, Eadie K, Konings M, et al. Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim. J Antimicrob Chemother. 2020. PMID: 31904836. doi:10.1093/jac/dkz529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。